SWOG clinical trial number
SWOG-8795 (INT-0094) (EST-1888)

Randomized Prospective Comparison of Bacillus Calmette-Guerin and Mitomycin-C Therapy and Prophylaxis in Superficial Transitional Cell Carcinoma of the Bladder with DNA Flow Cytometric Analysis

65% Accrual
Accrual
65%
Closed
Phase
65% Accrual
Accrual
65%
Published
Abbreviated Title
Randomized Prospective Comparison of Bacillus Calmette-Guerin and Mitomycin-C Therapy and Prophylaxis in Superficial Transitional Cell Carcinoma of the Bladder with DNA Flow Cytometric Analysis
Activated
12/01/1988
Closed
05/15/1992

Research committees

Genitourinary Cancer

Treatment

BCG Mitomycin-C

Other Clinical Trials

S2312
SWOG Clinical Trial Number

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature

Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
4% Accrual
Accrual
4%
Open
Phase
S2210
SWOG Clinical Trial Number

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
9% Accrual
Accrual
9%
Open
Phase
S2200
SWOG Clinical Trial Number

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2

Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
16% Accrual
Accrual
16%
Open
Phase